BACKGROUND: Direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or noncancer-associated venous thromboembolic disease. Although routine monitoring of these agents is not required, assessment of anticoagulant effect may be desirable in special situations. The objective of this review was to summarize systematically evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban, and edoxaban.
The development of an oral thrombin inhibitor (dabigatran) and oral factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) has changed the management of anticoagulation in patients with nonvalvular atrial fibrillation (AF) and VTE. As of January 2016, the American College of Chest Physicians (CHEST) and other organizations recommended these drugs over vitamin K antagonists as the agents of choice for management of noncancerassociated VTE. 1, 2 Guidelines from the American Heart Association, American College of Cardiology, and Heart Rhythm Society published in 2014 include vitamin K antagonists and direct oral anticoagulants (DOACs) for stroke prevention in AF but do not recommend one over the other. 3 Although these drugs, collectively referred to as DOACs, are administered in fixed doses and do not require routine laboratory monitoring for dose adjustment, [4] [5] [6] [7] there are a number of circumstances in which assessment of a DOAC's effect may be desirable. Some examples of when an assay with rapid turnaround time, if available, could directly impact patient care include emergent settings, such as life-threatening bleeding; requirement for epidural procedures; emergency surgery; and acute stroke in a patient who might otherwise be a candidate for thrombolysis. In other settings, such as overdose, GI malabsorption, extremes of body weight, drug interactions, acute renal injury, and treatment failure, a less rapid but precise assay would be desirable. 8 The anticoagulant effect of a DOAC is generally assumed to be directly proportional to its plasma concentration as measured by liquid chromatography/ tandem mass spectrometry (LC-MS/MS). LC-MS/MS is the most accurate way to assess drug concentration, but this technology is not widely available. The range of concentrations over which the DOACs have adequate or therapeutic anticoagulant effect is not known, although a number of studies have published results of pharmacokinetic analysis, including ranges of peak and trough levels in patients receiving therapy (Table 1) . We refer to levels within this range as the 'on therapy' range throughout this paper. Levels below the reported 5th percentile trough are referred to as below 'on therapy' range, and levels above the reported 95th percentile peak are referred to as above 'on therapy' range. The majority of patients are expected to have levels within the 'on therapy' range at any time during treatment. The most accurate assays are those that correlate best with LC-MS/MS results.
We previously published a systematic review evaluating the degree to which coagulation assays can help estimate the concentration (and therefore the effect) of dabigatran, rivaroxaban, and apixaban activity. Additionally, the American College of Chest Physicians published guidelines for quantification and screening in 2012, 10 as did the International Society on Thrombosis and Haemostasis (ISTH). 11 Since then, a number of studies have been published, and a third anti-Xa agent, edoxaban, has been approved. 12 Here, we update our previous systematic review with a broadened search strategy, the addition of data on edoxaban, and the inclusion of studies published between December 2, 2013, and July 1, 2015.
Materials and Methods

Literature Search
We performed a systematic review of the literature to examine use of coagulation assays for assessment of the anticoagulant activity of DOACs. A search of PubMed, Web of Science, and Embase from inception through July 1, 2015, was undertaken for dabigatran, rivaroxaban, apixaban, and edoxaban using the key words "name of drug" AND (monitoring OR measurement OR laboratory OR prothrombin time OR partial thromboplastin time OR activated partial thromboplastin time OR PT OR APTT). For anti-Xa agents (anti-Xa OR anti-factor Xa) were also included. For dabigatran (thrombin time OR TT or thrombin clot time OR TCT or dilute thrombin time OR dilute TT OR ecarin) were also included.
Study Selection
Articles were examined by title and abstract. A complete review of papers appearing to meet inclusion criteria was undertaken. We included studies that compared the results of one or more clinical coagulation assays with drug concentrations established either by measurement with direct LC-MS/MS or by LC-MS/MS-validated calibration standards. Studies performed on animals, studies published as abstracts only, and non-English-language articles were excluded. Reasons for exclusion are included in Figure 1 .
patient vs volunteer), number of samples, coagulation assays and reagents, and descriptors of the relationship between drug level and coagulation assay, were extracted and recorded in evidence tables.
Results
Dabigatran
Dabigatran etexilate is taken orally as an inactive nonpeptide prodrug and is rapidly converted by nonspecific esterases to a potent, direct inhibitor of freeand fibrin-bound thrombin. Absorption is rapid, but bioavailability is only 6.5%. The half-life is 12 to 14 hours, and elimination is 80% renal. 13 The expected steady-state concentrations of dabigatran as measured by LC-MS/MS are shown in Table 1 . Rivaroxaban is excreted partially by the kidneys (36%) and has a half-life of 6 to 13 hours, depending on the dose and the age of the recipient.
10,50-52,54
Study Selection: Of 1,648 articles identified in our search, 1,439 studies were excluded after title and abstract screening (Fig 1) . increasing concentrations (> 50-100 ng/mL). 63 Significant reagent-dependent differences in assay sensitivity were noted in multiple studies. Apixaban, a direct inhibitor of coagulation factor Xa, is a small molecule with 50% oral bioavailability. In healthy volunteers, apixaban achieves its peak plasma concentration approximately 3 hours after ingestion. Apixaban pharmacokinetics is not affected by food intake, and apixaban is highly protein bound in the plasma. 94 Because apixaban metabolism occurs via several different routes, this drug is less dependent on renal clearance than are other approved DOACs. In people with normal renal function, the half-life of apixaban is approximately 12 hours. 95 The expected steady-state concentrations of apixaban as measured by LC-MS/MS have been published 94 and are shown in Table 1 .
Study Selection: Our literature search yielded 898 titles. Of these, we excluded 863 that did not report original research, 17 published as abstract only, six that did not report levels measured by both LC-MS/MS and a coagulation assay, and one that did not involve human samples. The remaining 11 articles 55,60,61,67,77,96-101 met eligibility criteria (Fig 1) . Eligible studies collectively evaluated apixaban across a range of concentrations from 0 to 2,500 ng/mL (e- Table 3 ).
PT/INR:
Five studies 60, 96, [98] [99] [100] reported the relationship between PT and apixaban levels (e- Table 3 ). Two studies reported a linear or curvilinear relationship, 60, 96 and one found none. 99 Across in vitro and ex vivo samples and for a variety of reagents, PT was inadequately sensitive to apixaban, not only below but also substantially > 50 ng/mL.
APTT: Four studies 61,98-100 compared apixaban concentrations with APTT. A weak correlation between APTT and apixaban concentration was reported in one study. 36 All studies showed that the sensitivity of APTT is unacceptably low. All assays yielded normal times at apixaban concentrations of 100 ng/mL.
Anti-Xa Activity: Four studies 60,97-99 compared anti-Xa activity measurements with the plasma concentration of apixaban (e- Table 3) . The majority of studies demonstrated that anti-Xa activity varied linearly with apixaban concentration, but at least one study suggested that the correlation between anti-Xa activity and apixaban concentration may be less strong at low (15-50 ng/mL) concentrations. 99 Thrombin Generation: Three studies 77, 100, 101 compared thrombin generation assay results with the plasma concentration of apixaban (e- Table 3 ). Apixaban affected all parameters in a dose-dependent fashion, but sensitivity varied. There is insufficient evidence to recommend the use of thrombin journal.publications.chestnet.org generation for the assessment of apixaban effect in clinical practice.
Other Assays: Coagulation assays based on elastography or elastometry (eg, TEG and rotational thromboelastometry) showed some promise in their ability to detect the presence of apixaban.
20,43,55,100
Additional evidence will be needed before one or more of these assays can be recommended as the method of choice for detecting and quantifying the anticoagulant effect of any DOAC.
Edoxaban
Edoxaban is a direct inhibitor of factor Xa. Oral bioavailability is 62% and is not affected by food. Peak plasma concentration is achieved 1 to 2 hours after ingestion, and terminal half-life is 10 to 14 hours. Renal reported a relationship between the PT/INR and plasma edoxaban levels. Edoxaban prolonged the PT in a concentration-dependent, linear fashion, but assays were insufficiently sensitive at low therapeutic levels. Different PT reagents varied widely in their sensitivity to edoxaban.
109,113
APTT: Eight studies 105,108-111,113-115 reported a relationship between edoxaban levels and APTT. Edoxaban prolonged APTT in a dose-dependent manner with fair correlation in both in vitro and ex vivo studies. APTT was less sensitive to edoxaban than was PT. In some studies, edoxaban concentrations of 300 to > 600 ng/mL were needed to double the APTT from baseline, depending on the reagent.
Anti-Xa Activity: A relationship between anti-Xa activity and edoxaban levels was reported in nine studies. 104 reported a relationship between edoxaban levels and the thrombin generation assay using the Calibrated Automated Thrombogram system (Thrombinoscope BV). Edoxaban decreased peak thrombin generation, mean rate, and ETP and increased lag time and time to peak in a concentration-dependent manner. The thrombin generation assay was more sensitive to edoxaban than were PT and APTT. Peak thrombin generation and mean rate were the most sensitive parameters.
Other Assays: One study each reported a relationship between edoxaban concentration and DRVVT, 113 PiCT, 113 and TT. 104 None of these tests demonstrated adequate sensitivity or had adequate data to support routine use either for excluding the presence of edoxaban or for determining edoxaban concentration.
Discussion
Although there are no established therapeutic ranges for any of these drugs or evidence to support routine monitoring with or without titration of dose, there are a variety of circumstances in which assessing anticoagulant effect may be useful. A number of professional societies, including the ISTH and CHEST, have published recommendations for urgent or routine assessment of the anticoagulant effects of direct thrombin inhibitors and anti-Xa agents. In this systematic review, we have examined and presented evidence regarding the usefulness of a variety of coagulation assays to assess the anticoagulant activity of dabigatran, rivaroxaban, apixaban, and edoxaban.
Summary of Available Data
Dabigatran: The dilute TT and ecarin-based clotting assays provide the best correlation with plasma concentration. A normal TT excludes the presence of dabigatran. APTT is often, but not always, prolonged by the presence of trough-like or greater concentrations of dabigatran (Table 2) .
Rivaroxaban: Calibrated anti-factor Xa assays provide the best correlation with plasma concentration. Some PT assays correlate well with rivaroxaban concentration, but many do not. A prolonged PT with no other explanation in a patient treated with rivaroxaban indicates drug presence; however, a normal PT does not exclude the possibility of 'on therapy' or greater rivaroxaban concentrations (Table 2) .
Apixaban: Calibrated anti-factor Xa assays provide the best correlation with plasma concentration. Most PT and APTT assays poorly reflect the anticoagulant effect of apixaban. PT and APTT are not useful to assess whether apixaban is present in clinically important or greater quantities (Table 2) .
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Edoxaban: Calibrated anti-factor Xa assays provide the best correlation with plasma concentration. For edoxaban, PT is more sensitive than APTT, but there is interreagent variability, and some PT assays are insensitive at trough-like concentrations. A prolonged PT with no other explanation in a patient treated with edoxaban indicates drug presence; however, a normal PT does not exclude the possibility of 'on therapy' edoxaban concentrations (Table 2) .
Recommendations for Screening and Quantification
Although clinicians should resist the temptation to check levels routinely in the majority of patients because there is no evidence-based approach to interpret or act on these levels, there are circumstances in which assessment of DOAC effect is desirable. A screening assay may be useful in a setting in which a clinician needs to determine quickly the presence or absence of the drug (eg, prior to considering administration of thrombolytics or preoperatively in an urgent or emergent situation). Quantification may be desirable in the setting of uncertain absorption (eg, after bariatric surgery) or abnormal drug clearance (ie, acute kidney injury). We acknowledge that many hospitals may not have rapid access to the assays we recommend later and wish to emphasize that time elapsed since last dose, interpreted in light of possible drug interactions and the patient's renal and hepatic function, remains a key factor in estimating DOAC effect at any given moment.
Direct Thrombin Inhibitor: Dabigatran
Guidelines published by the ISTH recommend APTT as the test of choice for screening and TT as the test of choice for quantification; CHEST recommends the TT and ECT, respectively. 10,11 Our review of the data suggests that APTT is not sensitive enough to be used routinely for either screening or quantification with a curvilinear dose response; for many assays, APTT remains within normal limits even at therapeutic drug concentrations. TT is a more useful screening tool because normal TT can exclude the presence of a direct thrombin inhibitor but may be prolonged even at clinically nonsignificant levels and is too sensitive for quantification. Ecarin-based assays demonstrate more linear dose-response curves, suggesting usefulness for quantification within the 'on therapy' range, although, as with many other assays, reliability decreases at high and low drug concentrations, diminishing their usefulness. Dilute TT assays demonstrate linear dose-response curves with a high degree of correlation.
Unfortunately, availability of the dilute TT is limited. One survey of 592 Australasian coagulation laboratories revealed that only nine offered this test. 116 A 2015 survey of 46 specialized coagulation laboratories in North America reported that 22% offered a commercial dilute TT assay for measurement of dabigatran and 6% offered a homemade assay for this purpose; 15% reported offering TT assays, and 9% reported offering ecarin-based assays. 117 Availability in smaller laboratories and community hospitals is likely to be significantly less. Additionally, these assays are not approved by the US Food and Drug Administration for the quantification of dabigatran and must be interpreted in this light.
In these cases, of the assays likely to be available immediately for screening purposes, we favor APTT over PT. However, the clinician should be aware that most APTT assays will be inadequately sensitive to rule out the presence of 'on therapy' levels of the drug. In the ideal scenario, the clinical laboratory would have previously performed a dose-response study to define the sensitivity of the local APTT method.
Xa Inhibitors: Rivaroxaban, Apixaban, Edoxaban ISTH guidelines favor PT as the test of choice for screening and anti-Xa assay as the test of choice for quantification of rivaroxaban and apixaban. 11 CHEST favors anti-Xa for quantification of both rivaroxaban and apixaban and recommends against the use of PT to screen for rivaroxaban but makes no recommendation regarding screening for apixaban. 10 Neither recommendation specifically addresses edoxaban. Our review of the data supports anti-Xa activity as the test of choice for quantification of all Xa inhibitors, provided that a standard curve established with drug-specific calibrators is used. Correlation between anti-Xa activity and drug concentration is weaker at very low or high concentrations, particularly for apixaban. Thrombin generation may be useful, particularly for rivaroxaban.
As with the assays discussed for dabigatran, we recognize that calibrated anti-Xa assays may not be available in urgent or emergent situations. A survey of coagulation laboratories administered in 2013 revealed that, of 300 centers offering an anti-Xa assay for heparin, only nine had an established standard curve for rivaroxaban. 118 During an update of this survey in 2016, an additional 19 laboratories reported use of anti-Xa assays for measurement of rivaroxaban levels. 119 A similar survey of 46 specialized coagulation assays in 2015 revealed that 39% offered anti-Xa assays for rivaroxaban and 22% offered this for apixaban. 117 Availability for edoxaban was not reported, and, again, availability in local hospitals is likely to be significantly lower. If the clinician needs only to exclude the presence of clinically important drug effect, an anti-Xa assay, even if not calibrated for the relevant DOAC, can be helpful: If no anti-Xa activity is detected, the presence of a clinically important concentration of an oral factor Xa inhibitor is excluded. In cases in which no anti-Xa activity measurement can be performed quickly, we favor PT over APTT for rivaroxaban and edoxaban. However, because interassay variability is also high in this setting, we recommend that, for institutions that will rely on PT to make urgent decisions in patients treated with rivaroxaban or edoxaban, the clinical laboratory should perform a dose-response study with calibration standards to define the sensitivity of the institutional PT assay in advance. Most assays will be inadequately sensitive to exclude clinically significant levels of drug. Both PT and APTT are inadequately sensitive for apixaban, so laboratory evaluation may be of little to no use in the absence of an anti-Xa level.
There are many limitations to the accurate and reliable laboratory assessment of the anticoagulant effect of DOACs. The most accurate assays are unavailable in many clinical settings, and standard coagulation assays, which are available, are often uninterpretable. Expanded availability and US Food and Drug Administration approval of precise assays, such as the dilute TT, ECT, and anti-Xa, is needed. Routine monitoring of renal and hepatic function and medication reconciliation for possible drug interactions in patients treated with DOACs is also essential.
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